SLE set to enter a collaboration agreement with the University of Tasmania to licence breakthrough technology designed to reduce infant mortality

By 7th June 2017Uncategorised

SLE Ltd and the University of Tasmania have announced their intention to collaborate on the commercialisation of life saving technology, aimed at new-born infants that have to be provided with artificial respiration and oxygen.

The technology that has been developed over the last nine years by a team of scientists lead by Prof. Peter Dargaville (left) of the Tasmanian Health Service and Dr Tim Gale of the School of Engineering and ICT at the University of Tasmania, uses a closed-loop control algorithm to maintain an optimised oxygen concentration in the blood circulation of infants. This technology can be integrated to devices that provide respiratory support to infants.

Past multi centre studies have shown that vulnerable infants are very susceptible to changes in the oxygen in their circulation and the maintenance of this blood oxygen in a narrow but critical band may reduce mortality, retinal damage and other long term effects. The closed loop technology keeps the infant within this tight range for an extended period of time without the intervention of clinical staff.

Trials of the technology demonstrated that use of the closed loop control improved the time an infant spent within this target range by 25%

Mr Bernard Nelligan, Managing Director of SLE commented “In conjunction with current and future respiratory devices designed and manufactured by SLE, the technology will make automated oxygen control accessible to many millions of infants worldwide. This is a very exciting breakthrough in this area of infant respiratory support and it is such an honour to be working with UTAS to deliver this technology to the world”

“We are delighted to see this international collaboration between the University of Tasmania, SLE and the Tasmanian Health Service take this important step forward,” Dr Darren Cundy, Director of the University’s Business Development & Technology Transfer unit, said.  “We believe that SLE is the ideal partner to help bring this life saving technology to market and we look forward to concluding the licence shortly.”